Reassement of the Lille consensus on treatment of chronic bronchitis exacerbation;Reacute;eacute;valuation du consensus de Lille pour le traitement des exacerbations de bronchite chronique

Medecine et Maladies Infectieuses

Volumn 31, Issue 4, 2001, Pages 211-228

  Gaillat, J ^a   Dabernat, H ^b  

^a 74011 Cedex ^*  (France)

^b CHU PURPAN   (France)

Author keywords

Betalactams; Exacerbation of chronic bronchitis; Fluoroquinolones; Macrolides

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFACLOR; CEFPODOXIME PROXETIL; CEFTIBUTEN; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN; CHLORAMPHENICOL DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DIRITHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NEW DRUG; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TETRACYCLINE; TROVAFLOXACIN;

ARTICLE; CHRONIC BRONCHITIS; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MEDICAL INFORMATION; NONHUMAN; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; VIRUS INFECTION;

EID: 0034997245     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(01)00180-9     Document Type: Article

References (74)

1. e conférence de consensus en thérapeutique anti-infectieuse de la SPILF, Lille Med Mal Infect. 21:(Suppl 3-8):1991.
2. Recommandations pour la prise en charge des BPCO. Rev Mal Resp. Suppl 2:1997;S3-S91.
3. Siafakas N.M., Vermeire P., Pride N.B., Paoletti P., Gibson J., Howard P., et al. ERS Consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir J. 8:1995;1398-1420.
4. Conduite à tenir devant une infection respiratoire basse communautaire de l'adulte. Rev Mal Resp. 16:1999;224-233.
5. COPD Guidelines. Thorax. 52:(Suppl 5):1997;S4-S28.
6. Definition, epidemiology, pathophysiology, diagnosis and staging of COPD. Am J Resp Care. 152:1995;S78-S121.
7. Guidelines for the management of chronic obstructive pulmonary disease. Modern Med Of Australia. 1995;132-146.
8. Balter M.S., Hyland R.H., Lowde, et al. Recommandations on the management of chronic bronchitis. Can Med Assoc J. 151:(Suppl 10):1994;7-23.
9. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K.M., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Int Med. 106:1987;196-204.
10. Mayaud Ch., Thremolières F. Recommandations pour la prise en charge anti-infectieuse des exacerbations de bronchite chronique. Med Mal Infect. 26:1996;344-347.
11. Grossman R.F. Acute exacerbations of chronic bronchitis. Hospital Practice. 1997;85-94.
12. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 108:1995;43S-52S.
13. Murphy T.F., Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Resp Dis. 146:1992;1067-1083.
14. Eller J., Ede A., Schaberg T., Niederman M.S., Mauch H., Lode H. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest. 113:1998;1542-1548.
15. Monso E., Ruiz A., Rosell J., Manterola J., Fiz J., Morera J., Ausina V. Bacterial infection in chronic obstructive pulmonary disease. Am J Resp Crit Care. 152:1995;1316-1320.
16. Fagon J.Y., Chastre J., Trouillet J.L., Domart Y., Dombret M.C., Barnet M., Gibert C. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis. 142:1990;1004-1008.
17. Mc Farlane J., Prewett J., Rose D., Gard P., Cunningham R., Saikko P., et al. Prospective case control study of role of infection in patients who reconsult after initial antibiotic treatment for lower respiratory tract infection in primary case. BMJ. 315:1997;1206-1210.
18. Saint S., Bent S., Vittinghoff E., Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA. 273:1995;957-960.
19. Chodosh S., Schreurs A., Siami G., Barkman H.W., Anzueto A., Shan M., et al. Efficacy of oral Ciprofloxacin vs Clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Inf Dis. 27:1998;730-738.
20. Chodosh S., Mc Carty J., Farkas S., Drehobl M., Tosiello R., Shan M., et al. Randomized, double blind study of Ciprofloxacin and Cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Inf Dis. 27:1998;722-729.
21. Anzueto A., Niederman M.S., Tillotson G. Etiology, susceptibility and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg BID versus Clarithromycin 500 mg BID. Clin Therapeut. 20:1998;885-900.
22. Grossman R., Mukherjee J., Vaughan D. A 1 year community based health economic study of Ciprofloxacin versus usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 113:1998;131-141.
23. Ball P., Tillotson G.S. Lower respiratory tract infection therapy: the role of Ciprofloxacin. Journ Inter Med Research. 23:1995;315-327.
24. Chodosh S., Lakshminaragan S., Swarz H., Breish S. Efficacy and safety of 10 day course of 400 or 600 mg of Grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10 day course of 500 mg of Ciprofloxacin twice daily. Antimicrobial Agent Chemother. 42:1998;114-120.
25. Shah P.M., Maesen F.P., Dolmann A., Vetter N., Fiss E., Wesh R. Levofloxacin versus Cefuroxime Axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double blind study. Jour Antimicrob Chemother. 43:1999;529-539.
26. Leophonte P., Baldwin R.J., Pluck N. Trovafloxacin versus Amoxicilline/Clavulanic acid in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol Infect Dis. 17:1998;434-440.
27. Langan C.E., Cranfield R., Breisch S., Pettit R. Randomized, double blind study of Grepafloxacin versus Amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. Jour Antimicrobial Chemother. 40:1997;63-72.
28. O'Doherty, Daniel R, and the Trovafloxacin study group. Treatment of acute exacerbations of chronic bronchitis: comparison of Trovafloxacin and Amoxycillin in a multicentre, double blind double dummy study. Eur J Clin Microbial Infect Dis 1998 ; 17 : 441-446.
29. Allegra L., Konietzko N., Leophonte P., Hosie J., Pauwels R., Guyen J.N., Petipret P. Comparative safety and efficacy of Sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double blind, randomized, parallel, multicentre study. Jour Antimicrob Chemother. 37:(Suppl A):1996;93-104.
30. De Abate C.A., Henry D., Bensch G., Jubran A., Chodosh S., Harper L., et al. Sparfloxacin versus Ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. Chest. 114:1998;120-130.
31. De Abate C.A., Russel M., Mc Elvaine Ph., Faiss H., Upchurch J., Fawler C.L., et al. Safety and efficacy of oral Levofloxacin versus Cefuroxime Axetil in acute bacterial exacerbations of chronic bronchitis. Resp Care. 42:1997;206-213.
32. Habib M.P., Gentry L.O., Rodriguez Gomez G., Morowitz W., Polak E., Rae J.K., et al. Multicenter randomized study comparing efficacy and safety of oral Levofloxacin and Cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Inf Dis In Clin Pract. 7:1998;101-109.
33. Martin S.J., Meyer J.M., Chuck S.K., Pendland S.L. Levofloxacin and Sparfloxacin. Ann Pharmacother. 32:1998;320-336.
34. Anzueto A., Jenkinson S.G. Safety and efficacy of Clarithromycin versus Cefuroxime Axetil in the treatment of acute bacterial exacerbation of chronic bronchitis. Imm Infect Dis. 3:1993;231-237.
35. Guay D.R., Craft J.C. Comparative safety and efficacy of Clarithromycin and Ampicillin in the treatment of out patients with acute bacterial exacerbation of chronic bronchitis. J Intern Med. 231:1992;295-301.
36. Wettenyel R., Vetter N., Waardenburg F.A. Clarithromycin versus Cefaclor for the treatment of mild to moderate acute bacterial bronchitis. J Antimicrob Chemother. 31:1993;963-972.
37. Leophonte P., Chauvin J.P. Comparaison de l'efficacité et de la tolérance de la Clarithromycine et du Cefpodoxime proxetil dans le traitement des surinfections aiguës des bronchopneumopathes chroniques obstructifs. Med Mal Inf. 26:1996;846-854.
38. Mertens J.C., Van Barneveld P., Asin H.R., Ligtvoet E., Visser M.R., Branger T., Hoepelman A. Double blind, randomized study comparing the efficacies and safeties of a short (3-day) course of Azithromycin and a 5 day course of Amoxicillin in patients with acute exacerbation of chronic bronchitis. Antimicrobial Agents Chemother. 36:1992;1456-1459.
39. Laurent K. Efficacy and tolerability of Azithromycin versus Roxithromycin in the treatment of acute lower respiratory tract infections. Jour Antimicrob Chemother. 37:(Suppl C):1996;115-124.
40. Hoepelman I.M., Möllers M.J., Van Schie M.H., Greefhorst A.P.M., Schlesser N.J.J., Sinninghe Damste E.J., et al. A short (3 day) course of Azithromycin tablets versus a 10 day course of Amoxicillin-Clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long term outcome. Int J Antimicrob Agent. 1998;141-146.
41. Beghi G., Ferni F., Carractu L., Casalini A., Consigli G., D'Anto M., et al. Efficacy and tolerability of Azithromycin versus Amoxicillin-Clavulanic and in acute purulent exacerbation of chronic bronchitis. J Chemother. 7:1995;146-152.
42. Gaillat J. A multicentre study comparing safety and efficacy of Dirithromycin with Erythromycin in the treatment of bronchitis. Jour Antimicrob Chemother. 31:(Suppl C):1993;139-151.
43. Sides G. Clinical efficacy of dirithromycine in acute exacerbations of chronic bronchitis. Jour Antimicrob Chemother. 31:(Suppl C):1993;131-138.
44. Van Royen P., Betz N., Taziaux P., Vanden Hawte M., Poelman M. Dirithromycin versus Amoxiclav in the treatment of acute exacerbations of chronic bronchitis. Jour Intern Med Res. 25:1997;33-40.
45. Wasilewski M.M., Johns D., Sides G. Five day Dirithromycin therapy is as effective as seven day Erythromycin therapy for acute exacerbations of chronic bronchitis. Jour Antimicrob Chemother. 43:1999;541-548.
46. Hosie J., Quinn P., Smits P., Sides G. A comparison of 5 days of Dirithromycin and 7 days of Clarithromycin in acute bacterial exacerbation of chronic bronchitis. Jour Antimicrob Chemother. 36:1995;173-183.
47. Leroyer C., Boussac J., Lode H., Smits J.P.H., Sides G. A comparison of 5 days of Dirithromycin and 7 days of Roxithromycin in acute bacterial exacerbation of chronic bronchitis. Imm Infect Dis. 5:1995;149-155.
48. Raffi F. Bronchite aiguë et surinfection de bronchite chronique. L'Azithromycine, son efficacité en situation quotidienne. Med Mal Infect. 26:1996;1182-1187.
49. Cooper B.C., Mullins P.R., Jones M.R., Lang S.D.R. Clinical efficacy of Roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to H. influenzae. A meta-analysis. Drug Invest. 7:1994;299-314.
50. Vogel F., Drosez W., Vondra V., Rersenberg K., Marr C., Staley H. Sequential therapy with Cefuroxime followed by Cefuroxime Axetil in acute exacerbations of chronic bronchitis. Jour Antimicrob Chemother. 40:1997;863-871.
51. Langan C., Clercner B., Cazzola C.M., Brambilla C., Holmes C.Y., Staley H. Short course Cefuroxime Axetil therapy in the treatment of acute exacerbations of chronic bronchitis. Int J Clin Pract. 52:1998;289-297.
52. Guest N., Langan C.E. Comparison of the efficacy and safety of a short course of Ceftibuten with that of Amoxycilline/Clavulanate in the treatment of acute exacerbation of chronic bronchitis. Antimicrob Agents. 10:1998;49-54.
53. Aubier M.A. Comparison of Ceftibuten versus Amoxicllin/ Clavulanate in the treatment of acute exacerbations of chronic bronchitis. Chemother. 43:1997;297-302.
54. Philipps H., Van Hook C.J., Butler T., Todd W.M. A comparison of Cefpodoxime proxetil and Cefaclor in the treatment of acute exacerbation of COPD in adults. Chest. 104:1993;1387-1392.
55. Mc Adoo M.A., Rice K., Gordon G.R., Shan S.A. Comparison of Ceftibuten once daily and Amoxicillin/Clavulanate 3 times daily in the acute exacerbations of chronic bronchitis. Clin Therapeutics. 20:1998;88-100.
56. Ziering N., Mc Evlaine P. Randomized comparison of once daily Ceftibuten and twice daily Clarithromycin in the treatment of acute exacerbation of chronic bronchitis. Infection. 26:1998;69-75.
57. Dellamonica P., Roman A., Chiche D., Gilot C. Traitement des exacerbations de bronchites chroniques : Cefuroxime IM avec relais per os par Cefuroxime Axetil versus Ceftriaxone. Med Mal Infect. 27:1997;294-300.
58. Pines A. Successful treatment of respiratory tract infections in patients with chronic respiratory disease. How to make objective conclusions ? Jour Antimicrob Chemother. 9:1982;165-169.
59. Wilson R. Clinical studies in chronic bronchitis: a need for better definition and classification of severity. J Antimicrob Chemother. 37:1996;205-207.
60. Anzueto A., Ritzo J.A., Grossman R.F. The infection free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin Inf Dis. 28:1999;1344-1345.
61. Mc Farlane J.T., Colville A., Guion A., Mac Farlane R.M., Rose D.H. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet. 341:1993;511-514.
62. Stadley H., Mc Dade H.B., Paes D. Is an objective assessment of antibiotic therapy in exacerbation of chronic bronchitis possible? J Antimicrob Chemother. 31:1993;193-199.
63. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. Jour Antimicrob Chemother. 43:(Suppl A):1999;97-105.
64. Wilson R. Acute exacerbations of chronic bronchitis. Jour Antimicrob Chemother. 43:(Suppl A):1999;95-96.
65. Goldsmith C.E., Moore J.E., Murphy P.G., Ambler J.E. Increased incidence of Ciprofloxacin resistance in Penicillin resistant pneumococci in Northern Ireland. Jour Antimicrob Chemother. 41:1998;420-421.
66. Chen D.K., Mc Geer A., Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada. N Engl J Med. 341:1999;233-239.
67. Ho P.L., Que T.L., Ngai-Chong Tsang D., Tak Keung N.A., Chow K.H., Seto W.H., et al. Emergence of Fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother. 43:1999;1310-1313.
68. Guillemot D., Carbon C., Balkav B., Geslin P., Lecoeur H., Vaurelle Keruroedan F., et al. Low dosage and long treatment duration of β lactam: risk factors for the carriage of Penicillin resistant Streptococcus pneumoniae. JAMA. 279:1998;365-370.
69. Goldstein F.W. Penicillin resistant Streptococcus pneumoniae: selection by both β lactam and non β lactam antibiotics. Jour Antimicrob Chemother. 44:1999;141-144.
70. Prescription et consommation des antibiotiques en ambulatoire. Concours Med. 121:1999;760-768.
71. Le Fur Ph, Sermet C. Bronchopneumopathies aiguës et antibiothérapie en 1992. CREDES Mars 1995, biblio n° 1062.
72. Pechevis M., Fagnani F., Brin S., Dezelicourt M., Morales M. Infections respiratoires récidivantes du sujet atteint de bronchite chronique obstructive : prise en charge médicale et coûts. Rev Mal Resp. 13:1996;507-512.
73. Destache C.J., Dewan N., O'Donohue W.J., Campbell J.C., Angelillo V.A. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. Jour Antimicrob Chemother. 43:(Suppl A):1999;107-113.
74. Gravil J.H., Rawas O.A., Cotton M.M., Flanigan U., Irwin A., Stevenson R.D. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. Lancet. 351:1998;1853-1855.